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Gene directed-enzyme prodrug therapy (GDEPT) is an approach for sensitization of tumor cells to an enzymatically activated,
otherwisenontoxic,prodrug.CytochromeP4502B1(CYP2B1)metabolizestheprodrugscyclophosphamide(CPA)andifosfamide
(IFA) to produce the cytotoxic substances phosphoramide mustard and isophosphoramide mustard as well as the byproduct
acrolein. We have constructed a retroviral promoter conversion (ProCon) vector for breast cancer GDEPT. The vector allows
expression of CYP2B1 from the mouse mammary tumor virus (MMTV) promoter known to be active in the mammary glands of
transgenic animals. It is anticipated to be used for the generation of encapsulated viral vector producing cells which, when placed
inside or close to a tumor, will act as suppliers of the therapeutic C Y P 2 B 1p r o t e i na sw e l la so ft h et h e r a p e u t i cv e c t o ri t s e l f .T h e
generated vectorwaseﬀectivelypackagedbyvirusproducingcellsandallowedtheproductionofhighlevelsofenzymatically active
CYP2B1 in infected cells which sensitized them to killing upon treatment with both IFA and CPA. Determination of the respective
IC50 values demonstrated that the eﬀective IFA dose was reduced by sixteen folds. Infection eﬃciencies in vivo were determined
using a reporter gene-bearing vector in a mammary cancer cell-derived xenograft tumor mouse model.
Copyright © 2008 Reinhard Klein et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Conventional cancer chemotherapy including chemotherapy
of breast cancer often results in severe systemic toxicity at
drug concentrations necessary for eﬀective killing of tumor
cells. This obstacle can be overcome with the concept of
gene-directed enzyme prodrug therapy (GDEPT) that im-
plies selective delivery into tumor cells and expression of
drug-metabolizing transgenes within them [1].
The oxazaphosphorine cyclophosphamide (CPA) and
its structural isomer ifosfamide (IFA) are DNA-alkylating
agents commonly used in breast cancer chemotherapy [2].
These anticancer agents are administered as prodrugs that
are primarily activated by the hepatic enzyme cytochrome
P450 (CYP). Among the P450 enzymes, the subfamily 2B en-
zymes CYP2B1 (from rat) and CYP2B6 (from human) have
been shown to be the most active catalysts for this enzy-
matic reaction [3, 4]. The generated anticancer metabolites
phosphoramide mustard (from CPA) or isophosphoramide
mustard (from IFA) as well as acrolein are systematically dis-
tributed throughout the body eventually reaching the tumor
but also causing undesired toxic side eﬀects. Local activation
of cyclophosphamide or ifosfamide at the site of the tumor
would allow to use lower concentrations of the prodrug re-
sulting in lower systemic toxicity with a still eﬀective or, if
using conventional prodrug dosages, a much more potent
cell killing eﬀect on the tumor cells. In addition, cyclophos-
phamide and ifosfamide suicide gene therapy has the advan-
tageofalsoexertingabystandereﬀectasitcausesthedeathof2 Journal of Biomedicine and Biotechnology
not only the therapeutic transgene-carrying cells but also of
neighboring nontransgenic cells via passive diﬀusion of the
cytotoxic metabolites [5, 6].
Genetherapyrequiresstrongand,ifpossible,selectiveex-
pressionofthetransgeneintherequestedtissueororgan.For
mammary gland-speciﬁc expression of transgenes in mam-
mals,anumberofpromotersfromvarioussourceshavebeen
evaluated. Among those are the promoters of milk protein-
encoding genes such as the whey acidic protein (WAP), β-
lactoglobulin, α-s1-casein, β-casein, or the C3(1) promoter
[7]. However, for mouse models of human breast cancer,
the long terminal repeat (LTR) of the mouse mammary tu-
mor virus (MMTV) has emerged as the most potent and fre-
quently used promoter to drive transgene expression [8–12].
It, therefore, also represents one of the major candidate pro-
moters for human breast cancer gene therapy. The MMTV
promoter is most active during lactation due to induction by
lactogenichormonessuchasprolactin[13,14].However,the
most potent inducing eﬀects are due to the presence of hor-
mone response elements (HREs) within the U3 region of the
viral LTR that respond to androgens, progestins, mineralo-
corticoids, and glucocorticoids [15].
For in vitro and in vivo transgene delivery, a number
of techniques have been elaborated. Among those, infection
with retroviral vectors represents a very eﬃcient method.
Due to their capacity to integrate into the host genome,
retroviral vectors are one choice if long-term gene expres-
sion of a transgene is desired and thus they have been used
in a variety of gene therapy studies [16]. However, to date,
several rounds of vector delivery are necessary to achieve
satisfactory transfer of a therapeutic gene in vivo. This is
mainly due to unsatisfactory virus titers, rapid clearance of
the vector by the liver and the spleen [17], and, in the case
of MLV-based retroviral vectors, the fact that only dividing
cells can be reached, thereby a priori limiting the number
of accessible cells [18]. In addition, repeated delivery may
cause the risk of the development of an immune response
against the vector, thereby impairing gene transfer. The es-
tablishment of an in situ cell depot, constantly producing
therapeutic retroviral vectors where required, may overcome
those hurdles and may allow much more eﬃcient delivery of
the transgene. In previous experiments, for proof of princi-
ple, we have encapsulated virus packaging cells that not only
expressed a reporter gene from a retroviral vector but also
produced virus particles. Upon insertion into the mammary
glands of mice, the virus particles were liberated from the
capsules and transferred the reporter gene to surrounding
cells [19].Thistypeofdeliveryhasalsobeenshownbyothers
to be functional using a potentially therapeutic suicide gene
forthetreatmentofglioblastoma[20],andsimilarlong-term
in vivo gene delivery could also be achieved using TheraCyte
immuno-isolation devices containing spleen necrosis retro-
virus packaging cells [21]. We have also shown previously
that, when combined with ifosfamide-based chemotherapy,
intratumoral injection as well as instillation of capsules con-
taining CYP2B1-expressing (but not virus-producing) cells
into tumor-supplying blood vessels leads to a signiﬁcantly
increased tumoricidal eﬀect on experimentally generated tu-
mors in mice [22, 23] or on inoperable pancreatic tumors in
humans [24, 25].
In this study, we have constructed MLV-based repli-
cation-deﬁcient retroviral promoter conversion (ProCon)
vectors for the use in breast cancer gene therapy in com-
bination with the in situ vector supply and delivery sys-
tem described above. The vectors are designed to express
the CYP2B1 gene within the packaging cells to convert the
prodrugs ifosfamide or cyclophosphamide into their active
forms. In addition, the packaging cells produce virus parti-
cles that are liberated from the cells and, by infection, can
transfer the therapeutic gene into the surrounding target
cells. In the vectors described in this study, the original U3
region of the 3 long terminal repeat (LTR) is replaced with
the heterologous MMTV promoter. In virus-packaging cell
lines, transcription of the eGFP-encoding reporter gene or
of the actual therapeutic CYP2B1-encoding gene is driven by
the MLV promoter/enhancer. After infection, in the course
of reverse transcription, the heterologous MMTV promoter
is duplicated and one copy is translocated to the U3-region
of the 5 LTR. This rearrangement ﬁnally brings the expres-
sionofthetransducedgeneundercontroloftheMMTVpro-
moter. We show that the genes incorporated into the vectors
are eﬃc i e n t l ye x p r e s s e di nv i r u sp a c k a g i n gc e l l sa sw e l la si n
infectedcells.Virustitersobtainedwiththegeneratedvectors
are suﬃciently high to allow eﬃcient infection of target cells
both in vitro and in a murine tumor model in vivo. We fur-
ther show that the generated therapeutic CYP2B1 protein is
enzymatically active and exerts a strong cell killing eﬀect on
infected breast cancer cells upon treatment with ifosfamide
or cyclophosphamide in vitro.
2. MATERIALS AND METHODS
2.1. Plasmids
PlasmidspPCCMm1andpPCEMm1(seeFigure 1)ar eid e n-
tical in construction except for the fact that pPCCMm1 car-
ries the Cyp2B1 gene and pPCEMm1 carries the eGFP gene.
pPCCMm1 was constructed by replacing a cytomegalovirus
(CMV) promoter-harboring MluI–SacII fragment of plas-
mid pPCCmCMV.WPRE (Harry Holzm¨ uller, Austrianova
Biotechnology GmbH) with an MluI–SacII fragment from
plasmidpPCEMa[26]harboringtheMMTVpromoter.Plas-
midpPCEMm1wasconstructedasdescribedelsewhere[27].
pCMV-dsRed-Express was purchased from BD Clontech.
2.2. Nucleicacidextraction
Plasmid DNA was isolated using a QIAprep spin miniprep
kit (Qiagen, Calif, USA) or a Qiagen-tip 100 plasmid midi
kit (Qiagen). Linear DNA fragments were puriﬁed using a
QIAquick gel extraction kit (Qiagen).
2.3. Celllines
Human 2GP19Talf amphotropic retroviral packaging cells
[28], human 293 embryonic kidney cells (ATCC CRL-1573)Reinhard Klein et al. 3
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Figure 1: MLV-based retroviral ProCon vectors. 5 LTRs consist of unique 3 (U3), repeated (R), and unique 5 (U5) regions. 3 LTRs consist
of repeated (R) and unique 5 (U5) regions. The 3 LTR U3 region has been replaced by the MMTV promoter that drives expression of the
transgene (eGFP or CYP2B1) in infected cells. All vectors contain the CMV enhancer region (CMV enh) upstream of the 5 LTR, a packaging
region (ψ), an internal SV40 promoter (SV40) driving the expression of a neomycin resistance gene (neo), the Woodchuck hepatitis virus
posttranscriptional regulatory element (WPRE), and an origin of replication (ori) for replication in E. coli.
[29],andfelineCRFKkidneycells(ATCCCCL-94)[30]wer e
grown in Dulbecco’smodiﬁed Eagle’s medium (DMEM)/
Glutamax (Invitrogen Life Technologies, Calif, USA) sup-
plemented with 10% fetal bovine serum (FBS; Invitro-
gen Life Technologies). Human T-47D (mammary gland;
ductal carcinoma) cells (ATCC HTB-133) [31]w e r ec u l t i -
vated in DMEM/Glutamax supplemented with 10% FBS and
6.5μg/mL insulin (Sigma-Aldrich, Miss, USA).
2.4. Transfection
Transfections of 2GP19Talf cells were performed by calcium
phosphate coprecipitation according to the instructions of
the manufacturer (Amersham Biosciences, NJ, USA). For
stable transfections, the transfected cells were selected in
medium containing 0.4mg/mL Geneticin(G418; Invitrogen
LifeTechnologies)untilmock-transfectedcellshaddied.Sta-
bly transfected cells were maintained as populations in the
presence of 0.4mg/mLG418.
2.5. Invitroinfectionexperiments
Culturesupernatantsfrom2×106 virus-producingcellswere
usedto infect 4 ×105 target cells as described elsewhere [28].
For titer calculation, dilutions of infected CRFK cells were
trypsinized and replated 24 hours afterinfection in triplicates
and selected in medium containing 0.4mg of G418/mL.After
10to14daysofculture,drug-resistantcolonieswerecounted,
andthenumberofcolony-formingunits(CFU)permilliliter
ofvectorsupernatantwascalculated.Populationsofstablyin-
fected T-47D and CRFK cells were maintained in the pres-
ence of 0.4mg/mLG418. For stimulation of expression, cells
were treated with 1μM dexamethasone (Sigma-Aldrich) ev-
ery 48 hours.
2.6. Invivoinfectionexperiments
For establishment of mixed tumors 2GP19Talf/pPCEMm1
cells and T-47D/DsRed or CRFK/DsRed cells were
trypsinized out of the culture ﬂasks, washed three times with
PBS, and mixed in a ratio of 1:5 or 1:10. A total number
of 6 × 105 mixed cells in a total volume of 100μLR P M I
medium containing 100U/mL penicillin/streptomycin
(Invitrogen Life Technologies) and 50% matrigel (Becton
Dickinson Biosciences, NJ, USA) was injected into the
mammary fat pads of Hsd: Athymic Nude-nu mice (Harlan
Winkelmann, Borchen, Germany). For stimulation of tumor
growth, slow-release estrogen pellets (1.13mg/pellet, 60 days
release; Innovative Research of America, Fla, USA) were
implanted. At an average tumor size of 100–200mm3,m i c e
were treated with 500μg dexamethasone/mouse (Voren,
1mg/mL, Boehringer Ingelheim, Ingelheim, Germany) in-
traperitoneally on 3 consecutive days. On day 4, tumors were
explanted, digested to single-cell suspension by incubation
with 2mg/mL collagenase (Sigma-Aldrich) in PBS at 37◦C
for two hours, washed twice with DMEM/10% FBS, and
ﬁnally analyzed by ﬂuorescence-activatedcell sorting (FACS)
andconfocallaser-scanning microscopy. Invivoexperiments
were carried out according to Austrian law regulating animal
experimentation (GZ 68.205/109-BrGT/2003).
2.7. Detectionofﬂuorescentcells
For detection of DsRed- and EGFP-expressing tissue culture
cells, those were trypsinized, washed twice with PBS/10%
FBS, and then 50,000 cells per sample were analyzed for ﬂu-
orescencewith an FACS analyzer (FACScalibur; Becton Dick-
inson). Cells from explanted tumors were treated as de-
scribed above. The numbers and meanﬂuorescence inten-
sities (MFIs) of positive cells were determined using the
CellQuest software (Becton Dickinson). For confocal laser-
scanning microscopy, a Zeiss LSM 510 inverted microscope
equipped with a 40x, 1.3 numerical aperture, oil immer-
sion objective (Plan Neoﬂuar, Zeiss, G¨ ottingen, Germany)
was used. Cells analyzed by laser-scanning microscopy were
prepared in the same way as for FACS analysis.
2.8. FACSsorting
PopulationsofcellsexpressingtheﬂuorescentproteinsEGFP
or DsRed were FACS sorted to exclude nonﬂuorescent cells
before their use in in vivo experiments. Therefore, cells to be
sorted were expanded to approximately 3×107,h a rv e s t e db y
trypsinization, resuspended in normal cell culture medium,
and pelleted by cetrifugation at 410×g for 5 minutes. There-
after, cells were washed twice in PBS and resuspended in PBS
containing 5% FBS. Then, the cell suspension was ﬁltered
through a sterile nylon gauze into an FACS tube and stored
on ice until sorting. FACS sorting was performed using the
FACSVantage SE device (Becton Dickinson) which is con-
trolled by the Cell Quest Pro software (Becton Dickinson).4 Journal of Biomedicine and Biotechnology
2.9. Detectionofproteinandenzymaticactivity
CYP2B1 was detected by Western blotting using an anti-
CYP2B1 antibody (Daiichi Pure Chemicals Co., LTD, NJ,
USA). The enzymatic activity of CYP2B1 was determined in
a 96-well format resoruﬁn assay. Brieﬂy, cells were washed
twice with PBS, trypsinized out of the culture ﬂasks, and re-
suspended in DMEM/Glutamax medium lacking phenol red
(Invitrogen Life Technologies) supplemented with 10% FBS.
100 μL of cell suspension containing a total of 4 × 105 cells
was pipetted into a black clear bottom 96-well plate in qua-
druplicates. DMEM/Glutamax medium containing 10% FBS
but lacking phenol red was used as a blank. 5μLo fs u b -
strate (0.3mM benzylresoruﬁn in DMSO; Sigma-Aldrich)
was added to each well. Plates were incubated for 1 hour
at 37◦C/5% CO2 protected from light. Samples were ﬂuo-
rometrically analyzed for the presence of generated resoruﬁn
in a plate reader (Tecan Systems) using an extinction wave-
lengthof520nmandanemissionwavelengthof590nm.The
CYP2B1 enzymatic activities of a selected single cell clone
(22P1G) [32] served as a reference.
2.10. Cytotoxicityassays
1 × 104 T-47D or T-47D/pPCCMm1 cells were seeded into
96 well plates in quadruplicates and cultivated in DMEM/
Glutamax medium lacking phenol red (Invitrogen Life Tech-
nologies) supplemented with 10% FBS for six days without
changing the medium. 24 hours after seeding of the cells,
the medium was supplemented with 0, 0.03, 0.1, 0.3, 1, or
3mM ifosfamide (Baxter, Ill, USA) or cyclophosphamide
(Baxter). The supplementation with dexamethasone was re-
peated every 48 hours. Five days after incubation with ifos-
famide or cyclophosphamide, the viabilities of the cells were
determined with an XTT assay according to the instructions
of the manufacturer (Promega, Wiss, USA). The plates were
analyzed with a plate reader (Tecan Systems Inc., Calif, USA)
by reading the absorbance at 490nm.
3. RESULTS
3.1. ThegeneratedProConvectorsystemallows
efﬁcientinfectionoftargetcells
We have previously evaluated MLV-based ProCon vectors
(pPCEM and pPCEMm1) containing the mammary gland-
speciﬁcMMTVpromoterandtheeGFPgeneasareporterfor
their gene expression and infection capacities in vitro [27].
Here, for in vivo investigations of the eﬃcacy of the thera-
peutic vectors, we chose the following experimental setup:
we wanted to determine if eﬃcient infection of target cells is
(i) also achievable by cocultivation of virus-producing cells
and target cells in vitro instead of using high-titer virus sus-
pensions for in vitro infections and (ii) in a mixed tumor
model in vivo, thus mimicking a future therapeutic situation
in which viruses would be released from capsules. In 293-
based virus-producing 2GP19Talf cells, vector pPCEMm1
(see Figure 1)[ 27] that was used in this study allows the
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Figure 2: In vitro infection of T-47D/DsRed and CRFK/DsRed
cells with pPCEMm1. (a) FACS analysis of CRFK/DsRed and T-
47D/DsRed cells cocultivated with 2GP19Talf cells stably trans-
fected with pPCEMm1 over a time period of ﬁve weeks. The
numbers of red, green, and red/green ﬂuorescent cells of a repre-
sentative experiment are shown. As negative controls, 2GP19Talf,
T-47D, and CRFK cells were used. As positive controls, pure
2GP19Talf/pPCEMm1, T-47D/DsRed, and CRFK/DsRed cells were
used. (b) Confocal laser-scanning microscopy of CRFK/DsRed cells
cocultivated with 293/pPCEMm1 cells over a time period of ﬁve
weeks.Upperleft(UL),greenﬂuorescence;upperright(UR),trans-
mission; lower left (LL), red ﬂuorescence; lower right (LR), UL +
LL. Magniﬁcation 400x. (c) Confocal laser-scanning microscopy
of CRFK/DsRed cells cocultivated with 2GP19Talf/pPCEMm1cells
over a time period of ﬁve weeks. Upper left (UL), green ﬂuores-
cence; upper right (UR), red ﬂuorescence; lower left (LL), transmis-
sion; lower right (LR), UL + UR. Magniﬁcation 400x.
expression of the eGFP reporter gene from an MLV pro-
moter/CMV enhancer cassette while in infected cells after
promoter conversion, expression of the eGFP gene is drivenReinhard Klein et al. 5
by the heterologous MMTV promoter.
Forinvitroinfectionstudies,2GP19Talfvirus-producing
cells that had stably been transfected with pPCEMm1 were
m i x e di nr a t i o so f1:1 0o r1:5w i t hr e dﬂ u o r e s c e n th u m a n
T-47D breast cancer cells and as a control with red ﬂuores-
cent feline CRFK kidney cells that are known to eﬀectively
beinginfectedbyretroviruses.Redﬂuorescenceoftargetcells
was achieved by stably transfecting the cells with the DsRed
protein-encoding vector pCMV-dsRed-Express and enrich-
ment of red ﬂuorescent cells was performed by cell sorting.
Mixed cells were cocultivated for ﬁve weeks and the num-
bers of green, red, and green/red cells were monitored by
FACS (see Figure 2(a)). After ﬁve weeks, about 74% of red
ﬂuorescent T-47-D cells were also green ﬂuorescent, indicat-
ing that they had been infected with pPCEMm1. The ini-
tial ratio between virus-producing cells and target cells did
not play a role in this setting. The red ﬂuorescent CRFK
cells were infected to an extent of about 19% (ratio 1:10 be-
tween virus-producing cells and target cells) and 40% (ratio
1:5 between virus-producing cells and target cells). In con-
trast, when green ﬂuorescent nonvirus-producing 293 cells
stably infected with pPCEMm1 where mixed with red ﬂuo-
rescent T-47D or CRFK cells, only a very low number (<1%)
of false-positive red/green cells were detected by FACS af-
ter six weeks of cocultivation (data not shown). The ob-
tained results were also veriﬁed by confocal laser-scanning
microscopy: no red/green double ﬂuorescent cells could be
detected as exempliﬁed in Figure 2(b) for a mix of 293 cells
stably infected with pPCEMm1 and CRFK/DsRed cells. In
contrast, when the cell mixes of cocultivated red ﬂuorescent
T-47D or CRFK cells and virus-producing green ﬂuorescent
cells were analyzed, clearly a number of truly red/green dou-
ble ﬂuorescent cells could be detected as demonstrated for
a mix of CRFK/DsRed and 2GP19Talf/pPCEMm1cells (see
Figure 2(c)). Double ﬂuorescence was not due to red aut-
oﬂuorescenceof2GP19Talf/pPCEMm1orgreenautoﬂuores-
cenceof CRFK/pPCEMm1 and T-47D/pPCEMm1 cellssince
no red ﬂuorescent cells could be detected in samples only
consisting of green ﬂuorescent 2GP19Talf/pPCEMm1 cells
and no green ﬂuorescence could be detected in samples of
red ﬂuorescent CRFK/DsRed and T-47D/DsRed cells (data
not shown).
To investigate the in vivo infection capability of the
MMTV promoter containing ProCon vector, mixed tumors
consisting of DsRed-expressing T-47D or CRFK cells on the
one hand and virus-producing 2GP19Talf/pPCEMm1 cells
on the other hand were established in the mammary fat pads
ofnudemice.Again,theratiosbetweenvirus-producingcells
and target cells at the time point of injection were 1:10 and
1:5. After 11 weeks of tumor growth, the tumors were ex-
planted and analyzed by FACS (see Figure 3(a)). Of the red
ﬂuorescent T-47D cells of six mixed tumors, 22% to 55%
were also green ﬂuorescent, that is, had been infected with
pPCEMm1. A range of 13%–33% of red ﬂuorescent CRFK
cells isolated from mixed tumors also showed green ﬂuores-
cence, indicating infection by pPCEMm1. In addition, cells
were analyzed by confocal laser-scanning microscopy (see
Figures 3(b) and 3(c)). Clearly, cells ﬂuorescing red as well as
green were visible in the samples derived from mixed T-47D
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Figure 3: In vivo infection of T-47D/DsRed and CRFK/DsRed cells
with pPCEMm1. (a) FACS analysis of cells from explanted mixed
tumors consisting of 2GP19Talf/pPCEMm1 cells mixed with either
T-47D/DsRed or CRFK/DsRed cells. The numbers of red, green,
and red/green ﬂuorescent cells were determined. Percentages of
red/green doubleﬂuorescent cells for individual tumors are shown.
Individual tumors are designated with alphabetical characters be-
low each bar. (b)-(c) Confocal laser-scanning microscopy of cells
from explanted mixed tumors consisting of 2GP19Talf/pPCEMm1
and either T-47D/DsRed (b) or CRFK/DsRed cells (c). Upper left
(UL), green ﬂuorescence; upper right (UR), red ﬂuorescence; lower
left (LL), transmission; lower right (LR), UL + UR. Magniﬁcation
400x.
(see Figure 3(b)) as well as from mixed CRFK tumors (see
Figure 3(c)). As expected, cells originating from control tu-
mors solely consisting of 2GP19Talf/pPCEMm1 cells showed
only green but no red ﬂuorescence while cells stemming
from control tumors exclusively consisting of T-47D/DsRed
or CRFK/DsRed cells showed only red but no green ﬂuores-
cence. Cells derived from control tumors only consisting of
2GP19Talf, T-47D, or CRFK cells exhibited no ﬂuorescence
at all (data not shown).
3.2. TheProConvector/viruspackagingcell
systemisfunctional
The eGFP reporter gene was replaced with the therapeutic
gene coding for cytochrome P450 2B1 (CYP2B1). The re-
sulting vector pPCCMm1 (see Figure 1) was used to trans-
fect 2GP19Talf cells and vector harboring cells were selected6 Journal of Biomedicine and Biotechnology
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Figure 4: CYP2B1 expression, activity, and virus titers of 2GP19Talf amphotropic retroviral packaging cells stably transfected with pPC-
CMm1. (a) Expression of CYP2B1 in 2GP19Talf/pPCCMm1 cells. Cell lysates (equal amounts of protein) were analyzed by Western blotting
for the presence of CYP2B1 using an anti-CYP2B1 antibody. The CYP2B1 band is indicated with an arrow. The molecular weights of the
protein standard are given on the left side. Neg. cntrl.: 2GP19Talf cells not transfected with pPCCMm1. (b) Enzymatic activity of CYP2B1
in 2GP19Talf/pPCCMm1 cells. The enzymatic activity as determined by a resoruﬁn assay is shown as the relative emission intensity of the
created product resoruﬁn at 590nm in comparison to nontransfected cells (neg. cntrl.). (c) Virus titers of 2GP19Talf/pPCCMm1 cells as
determined by counting the numbers of colonies of infected G418-resistant CRFK cells (colony-forming units per milliliter; CFU/mL). Two
independentinfectionexperimentswereperformed.Platingofdilutionsofcellsafterinfectionwasperformedintriplicates,each.Neg.cntrl.:
2GP19Talf cells not transfected with pPCCMm1.
withgeneticininordertoobtainapopulationofstablytrans-
fected cells. Western blot analysis was used to prove that
CYP2B1 was produced in 2GP19Talf/pPCCMm1 cells (see
Figure 4(a)). To not only test for the presence of the protein
but also for its activity, resoruﬁn formation as a consequence
of CYP2B1 activity was monitored using a 96-well format as-
say.Generationofresoruﬁnin2GP19Talf/pPCCMm1cellsin
relation to 2GP19Talf negative control cells after incubation
with pentoxyresoruﬁn is shown in Figure 4(b).T h ep r e s e n c e
of resoruﬁn indicated that CYP2B1 was active.
For infection of target tumor cells, suﬃciently high num-
bers of virus particles have to be generated by the virus-
producing cells. Virus titers were determined by infection
of CRFK cells with virus particles from the supernatant of
2GP19Talf/pPCCMm1 cells and followed by counting the
numbers of G418 resistant colonies. Titers were about 1.3 ×
106 colony-forming units (CFU)/mL of cell supernatant (see
Figure 4(c)) which is comparable to titers obtained with the
respective eGFP gene-containing vector pPCEMm1 [27].
3.3. TheMMTVpromoterProConsystemgeneratesa
pronouncedcellkillingeffectinvitro
As a model breast cancer cell line to study the eﬃcacy of our
vector system, the T-47D cell line was chosen. T-47D cells
were infected with pPCCMm1 and stable populations were
created by selection of infected cells with G418. For induc-
tion of gene expression from the MMTV promoter cells were
stimulatedwithdexamethasonefor48hoursandanalyzedby
Western blotting for the presence of CYP2B1. While an anti-
CYP2B1 antibody did not detect any CYP2B1 in noninfected
T-47Dcells(negativecontrol),CYP2B1wasclearlypresentin
T-47D cells infected with pPCCMm1 (see Figure 5(a)). Re-
soruﬁn assays revealed that the protein was also active in that
cell line (Figure 5(b)). Enzyme activities were 2.5-fold higher
in cells that had been treated with dexamethasone compared
to those in nontreated cells (data not shown).
To evaluate the sensitizing eﬀect of CYP2B1 on T-47D
cellsupontreatmentwith theanticancerprodrug ifosfamide,
T-47DcellsinfectedwithpPCCMm1andnoninfectedT-47D
control cells were treated with increasing amounts of ifos-
famide (ranging from 0 to 3mM) for ﬁve consecutive days
after which cell viabilities were determined using an XTT
assay. While noninfected T-47D cells remained largely un-
aﬀected up to an ifosfamide concentration of 0.3mM, T-
47D/pPCCMm1 cells expressing the CYP2B1 gene showed
a marked decrease of 40% already at a concentration of
0.1mM. Thisviabilitydecreasedfurtherathigher concentra-
tions(seeFigure 6(a)).0.3mMifosfamidewasdeterminedas
the most eﬀective concentration at which noninfected T-47
cells were still largely unaﬀected but CYP2B1-producing T-
47D/pPCCMm1cellsshowedadramaticdecreaseinviabilityReinhard Klein et al. 7
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Figure 5: CYP2B1 expression and activity in T-47D cells stably infected with pPCCMm1. (a) Expression of CYP2B1 in a population of
T-47D/pPCCMm1 cells. Cell lysates (equal amounts of protein) were analyzed by Western blotting for the presence of CYP2B1 using an
anti-CYP2B1 antibody. The CYP2B1 band is indicated with an arrow. The molecular weights of the protein standard are given on the left
side.Neg.cntrl.:T-47DcellsnotinfectedwithpPCCMm1.(b)EnzymaticactivityofCYP2B1inapopulationofT-47D/pPCCMm1cells.The
enzymatic activity as determined by a resoruﬁn assay is shown as the relative emission intensity of the created product resoruﬁn at 590nm
in comparison to noninfected T-47D cells (neg. cntrl.) and a reference clone of virus-packing cells (22P1G).
by 88%. IC50 values were determined as 1.6mM and 0.1mM
for T-47D and T-47D/pPCCMm1, respectively. This repre-
sents a decrease of the IC50 value by sixteen folds, under-
lining the potent cumulative cytotoxic eﬀect of CYP2B1 and
ifosfamide.Treatmentofthecellswithcyclophosphamidein-
stead of ifosfamide led to similar results (see Figure 6(b)).
4. DISCUSSION
The ProCon vectors we have generated in this study are
a further development of an earlier, a β-galactosidase re-
porter gene-containing vector that was used for the gener-
ation of virus-producing cells for encapsulation experiments
[19]. The new vectors contain modiﬁcations that have re-
cently been shown by our laboratory to improve their over-
all performance (i.e., a CMV enhancer to increase viral RNA
production in virus-producing cells, a strong polyadenyla-
tion signal in the modiﬁed 3 LTR to prevent read-through
of viral RNA and to stabilize the mRNA, and an elon-
gated attachment site to increase the integration eﬃciency
of the provirus [26]). When transferred into virus pack-
aging cells, our newly generated vectors allow the produc-
tion ofenzymatically active CYP2B1that converts ifosfamide
or cyclophosphamide into their tumoricidal metabolites. As
demonstrated by Western blotting and with resoruﬁn assays,
a high concentration of CYP2B1 in virus-producing cells
is ascertained by the strong MLV promoter that drives the
expression of the therapeutic gene. Similarly, when incorpo-
rating the eGFP reporter gene into the vectors, high MFIs in
FACS analyses can be achieved in virus-producing cells. In
contrast to what was seen with similar vectors containing the
WAP promoter [27], when incorporated into our new vec-
tors, the woodchuck hepatitis virus posttranscriptional regu-
latory element (WPRE)enhancedthe expression rate of both
the eGFP and the CYP2B1 genes in virus packaging cells as
well as in infected cells (data not shown). Therefore, vec-
tors pPCCMm1 and pPCEMm1 harboring the WPRE were
chosen for further experiments over versions of those vectors
lacking the WPRE (data not shown).
pPCCMm1 and the reporter gene-harboring vector
pPCEMm1 allow the generation of high virus titers in virus-
packaging cells and productive infection of target cells in
vitro. In cocultivation experiments employing virus pack-
aging cells and target cells, the infection rates of T-47D
and CRFK target cells reached 74% and 40%, respectively.
The lower infection rate of the CRFK cells was due to the
higher growth rate of the CRFK cells compared to that of the
2GP19Talf/pPCEMm1 virus-packaging cells, quickly leading
tothedisplacementofthelatterones.Asaconsequence,virus
particle numbers in the cell supernatants decreased over
time. The infection rates were also reﬂected by similar results
obtained with confocal laser-scanning microscopy, demon-
strating true infection of target cells. The small numbers of
double ﬂuorescent cells (<1%) obtained after six weeks of
cocultivation of red ﬂuorescent target cells and green ﬂu-
orescent nonvirus-producing cells represented false-positive
cells since no such double ﬂuorescent cells were observed in
laser-scanning microscopy. Most likely, the small numbers8 Journal of Biomedicine and Biotechnology
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Figure 6: Enhanced cytotoxicities of ifosfamide and cyclophosphamide in T-47D/pPCCMm1 cells expressing CYP2B1. Cells were cultivated
at increasing amounts of ifosfamide for ﬁve days as described in materials and methods. Cell viabilities were determined using an XTT assay
and survival rates of CYP2B1 expressing cells in relation to noninfected control cells were calculated. (a) Incubation of cells with ifosfamide.
(b) Incubation of cells with cyclophosphamide.
of false-positive red/green cells observed in FACS experi-
ments were rather due to small numbers of red and green
cells sticking together, thus, giving the impression of double-
ﬂuorescent cells. This is also underlined by the fact that small
numbers of red/green ﬂuorescent cells were even detected
when red ﬂuorescent cells were mixed with green ﬂuorescent
cells immediately prior to FACS (data not shown).
Since in vivo infection may be less eﬃcient compared to
invitro infection, we tested our vectors in a mixed tumor
model in nude mice in vivo. Analysis of explanted tumors
revealed that 22% to 55% of T-47D target cells and 13%
to 33% of CRFK target cells had been infected with vector
pPCEMm1. The somewhat lower infection rate for CRFK
cells was probably due to their excellent growth rate in vivo
compared to the poor growth rate of the 293-based virus-
producing cells and a subsequent shift in the ratio between
virus-producing cells and target cells in favor of the target
cells. This probably led to a substantial decrease of virus titer
withinthetumorovertime.However,thiswillnotbeanissue
ifvector-producingcellswillbeencapsulated.Inaddition, an
infection rate of 100% is not necessarily required during a
therapy employing encapsulated viral vector-producing cells
because of the bystander eﬀect of cyclophosphamide or ifos-
famide on neighboring noninfected cells in GDEPT [6, 33].
Incorporation of the MMTV promoter into the retrovi-
ral vectors allowed high transgene expression of the eGFP
reporter gene or the therapeutic CYP2B1 gene in infected
cells. This was not only seen for T-47D and CRFK cells but
also for a number of other human or nonhuman cell lines
(mainly of mammary origin; data not shown). In most of the
cell lines, transgene expression could be further boosted by
stimulation with the glucocorticoid dexamethasone. Trans-
gene expression was also increased in most of the cell lines
when cells were treated with progesterone, although the ef-
fect was less pronounced (data not shown). Dexamethasone
is frequently used in cancer chemotherapy, either as a tumo-
ricidal therapeutic [34, 35] or to prevent or diminish nau-
sea and other side eﬀects in patients (including breast can-
cer patients) undergoing chemotherapy [36, 37]. Thus, in a
GDEPT setting, dexamethasone would decrease the symp-
toms of the side eﬀects of the chemotherapy and at the same
time increase the expression of the therapeutic gene from the
MMTV promoter.
In this study, we also showed that the level of enzy-
matically active CYP2B1 generated in infected cells with the
newly developed vectors is pronounced enough to create a
highly increased cell killing eﬀect on T-47D/pPCCMm1 cells
upon ifosfamide or cyclophosphamide treatment in vitro.
The enhanced cytotoxic eﬀect due to infection with pPC-
CMm1 became manifest in a sixteen fold-lowered IC50 value
for ifosfamide in T-47D/pPCCMm1 compared to nonin-
fected T-47D cells. This value was similar for cyclophos-
phamide. Eﬀective concentrations of 0.1–0.5mM ifosfamide
have been measured in the plasma of patients after adminis-
tration of typical dosages of ifosfamide during conventional
chemotherapy [38]. These pharmacologically active concen-
trations are identical to those we determined, which resulted
in eﬃcient killing of CYP2B1-expressing T-47D cells while
leaving T-47D cells not expressing CYP2B1 largely unaf-
fected.
Taken together, the newly generated vectors constitute
the basis for the development of a novel breast cancer
GDEPT system: the system is anticipated to employ the en-
capsulation of cells that (i) generate the therapeutic enzymeReinhard Klein et al. 9
CYP2B1 and, (ii) in addition, produce viral vector particles
that transfer the therapeutic CYP2B1 gene directly into tu-
mor cells.
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